DCTH Relative Valuation
DCTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DCTH is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for DCTH's competitors is 4.44, providing a benchmark for relative valuation. Delcath Systems Inc Corp (DCTH) exhibits a P/S ratio of 5.69, which is 28.00% above the industry average. Given its robust revenue growth of 530.26%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
BWMN
Bowman Consulting Group Ltd
25.610
USD
-2.92%
ANSC
Agriculture & Natural Solutions Acquisition Corp
10.750
USD
0.00%
KELYA
Kelly Services Inc
11.960
USD
-3.16%
TCBX
Third Coast Bancshares Inc
30.950
USD
-2.46%
TWFG
TWFG Inc
35.260
USD
-0.20%
CDXC
Chromadex Corp
7.920
USD
-0.89%
ARCT
Arcturus Therapeutics Holdings Inc
11.970
USD
-5.75%
GCO
Genesco Inc
21.330
USD
-6.69%
SWBI
Smith & Wesson Brands Inc
9.550
USD
-2.15%
MITK
Mitek Systems Inc
9.515
USD
-2.61%
FAQ
Is Delcath Systems Inc (DCTH) currently overvalued or undervalued?
Delcath Systems Inc (DCTH) is now in the Fair zone, suggesting that its current forward PE ratio of 238.49 is considered Fairly compared with the five-year average of 16.68. The fair price of Delcath Systems Inc (DCTH) is between 5.58 to 85.96 according to relative valuation methord.
What is Delcath Systems Inc (DCTH) fair value?
How does DCTH's valuation metrics compare to the industry average?
What is the current P/B ratio for Delcath Systems Inc (DCTH) as of May 21 2025?
What is the current FCF Yield for Delcath Systems Inc (DCTH) as of May 21 2025?
What is the current Forward P/E ratio for Delcath Systems Inc (DCTH) as of May 21 2025?